# Microbiome Immunotherapy Toxicity and Response Evaluation

> **NCT04107168** · — · UNKNOWN · sponsor: **CCTU- Cancer Theme** · enrollment: 1800 (estimated)

## Conditions studied

- Melanoma
- Renal Cancer
- Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Ipilimumab
- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04107168
- **Lead sponsor:** CCTU- Cancer Theme
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-08
- **Primary completion:** 2024-07-08
- **Final completion:** 2025-07-08
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2023-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04107168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04107168, "Microbiome Immunotherapy Toxicity and Response Evaluation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04107168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*